Cefonicid: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>David E. Volk
(New page: {{subpages}} {{Chem infobox |align=right |image=center|thumb|250px|{{#ifexist:Template:Cefadroxil.jpg/credit|{{Cefadroxil.jpg/credit}}<br/>|}} |width=250px |molnam...)
 
mNo edit summary
 
Line 26: Line 26:
== References ==
== References ==
<references/>
<references/>
{{CZMed}}
{{CZMed}}[[Category:Suggestion Bot Tag]]

Latest revision as of 06:00, 26 July 2024

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
(CC) Image: David E. Volk
cefonicid
IUPAC name: see chemistry section
Synonyms:
Formula: C18H18N6O8S3

 Uses: antibiotic drug

 Properties: beta-lactam

 Hazards: see drug interactions

Mass (g/mol): CAS #:
542.5660 61270-58-4


Cefonicid, also known as cefonicido and cefonicidum, is a second-generation cephalosporin type of antibiotic medication. It antibacterial activity is due to the core beta-lactam structure which interacts with penicillin-binding proteins within bacteria, thus distruption bacterial cell wall synthesis. It is sold under the brand names Monocid and Praticef. It is administered intravenously or intramuscularly for treatment of urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.


Chemistry

The IUPAC name of cefonicid is (6R,7R)-7-[(2-hydroxy-2-phenylacetyl)amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. Its chemical formula, C18H18N6O8S3, gives it a molecule mass of 542.5660 grams/mole. Like penicillins and other cephalosporins, cefonicid's antibacterial activity is due to the presence of a beta-lactam, which can react with penicillin-binding proteins through an acylation reaction.


References

The most up-to-date information about Cefonicid and other drugs can be found at the following sites.